Loading chat...

FL S1092

Bill

Status

Engrossed

2/26/2026

Primary Sponsor

Appropriations Committee on Health and Human Services

Click for details

Origin

Senate

2026 Regular Session

AI Summary

  • Authorizes podiatric physicians to perform procedures using cellular or tissue-based products not approved by the FDA for connective tissue, ligament, and tendon repair, wound care, or pain management
  • Requires cellular or tissue-based products to be retrieved, manufactured, and stored in FDA-registered facilities certified by organizations such as the American Association of Tissue Banks, and must contain viable cells verified by post-thaw analysis
  • Mandates podiatric physicians include a prominent notice in all advertisements stating the products are not FDA-approved and encouraging patients to consult their primary care provider
  • Requires signed informed consent forms detailing the treatment nature, FDA approval status, anticipated results, possible risks, and alternative treatments before performing procedures
  • Establishes a third-degree felony for podiatric physicians who use human cells or tissues derived from aborted fetuses or embryos, or who sell products created using cellular or tissue-based products

Legislative Description

Podiatric Medicine

Last Action

CS passed; YEAS 112, NAYS 0

3/10/2026

Committee Referrals

Rules2/19/2026
Appropriations Subcommittee on Health and Human Services2/12/2026

Full Bill Text

No bill text available